文献速递头颈部肿瘤放疗

碳离子再照射对比调强再放疗治疗复发头颈癌(CARE):随机对照试验

Carbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial.
PubMed 文献 · Radiat Oncol · 2020-08-05

CARE是一项单中心、双臂、前瞻性II期随机试验,计划最多纳入72例不可切除复发头颈癌患者,1:1随机接受再调强放疗(reIMRT)或碳离子再照射(reCIRT)。主要目标是评估治疗后6个月内≥III级急性/亚急性毒性是否低于35%,次要终点包括12个月局部和远隔无进展生存、总生存和生活质量。

要点

  • reIMRT是复发头颈癌标准局部治疗,但≥III级严重毒性发生率为30-40%。
  • CARE试验首次随机比较reCIRT与reIMRT的毒性和临床结局。
  • 主要终点为6个月内≥III级急性/亚急性毒性低于35%。

核心结论

  • CARE试验旨在验证reCIRT相比reIMRT能否降低复发头颈癌的严重毒性并改善局部控制、总生存和生活质量。

研究设计与样本

  • 单中心、双臂、前瞻性II期随机对照试验,计划最多72例不可切除复发头颈癌患者,按1:1随机分配至reIMRT或reCIRT组。

主要发现

  • 原文为试验方案,尚未报告主要结局结果。

关键数值与推荐

  • 主要目标值为研究治疗后6个月内≥III级急性/亚急性毒性(CTCAE v5.0)低于35%。
  • 再照射总剂量范围为51-60 Gy或Gy(RBE),主要取决于放疗间隔和危及器官累积剂量。
  • 个体化剂量处方由治疗放射肿瘤医生自行决定。
  • 次要终点包括再照射后12个月局部和远隔无进展生存、总生存和生活质量。

临床怎么用

  • reIMRT仍为不可切除复发头颈癌的标准局部治疗选择,但严重毒性发生率为30-40%。
  • reCIRT在此前回顾性研究中提示为可行且有效的治疗方式,CARE试验将提供随机证据。

局限性

  • 原文为试验方案,尚无疗效和毒性结果数据。
  • 单中心设计可能影响结果外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intensity-modulated re-radiotherapy (reIMRT) has been established as a standard local treatment option in patients with non-resectable, recurrent head and neck cancer (rHNC). However, the clinical outcome is unfavorable and severe toxicities (≥grade III) occurred in 30-40% of patients. The primary aim of the current trial is to investigate carbon ion reirradiation (reCIRT) compared to reIMRT in patients with rHNC regarding safety/toxicity as well as local control, overall survival (OS), and quality of life (QoL). METHODS: The present trial will be performed as a single center, two-armed, prospective phase II study. A maximum of 72 patients will be treated with either reIMRT or reCIRT to evaluate severe (≥grade III) treatment-related toxicities (randomization ratio 1:1). The primary target value is to generate less than 35% acute/subacute severe toxicity (≥grade III), according to the Common Terminology Criteria for Adverse Events v5.0, within 6 months after study treatment. The total dose of reirradiation will range between 51 and 60 Gy or Gy (RBE), depending primarily on the radiotherapy interval and the cumulative dose to organs at risk. Individual dose prescription will be at the discretion of the treating radiation oncologist. The local and distant progression-free survival 12 months after reirradiation, the OS, and the QoL are the secondary endpoints of the trial. Explorative trial objectives are the longitudinal investigation of clinical patient-related parameters, tumor parameters on radiological imaging, and blood-based tumor analytics. DISCUSSION: Recent retrospective studies suggested that reCIRT could represent a feasible and effective treatment modality for rHNC. This current randomized prospective trial is the first to investigate the toxicity and clinical outcome of reCIRT compared to reIMRT in patients with rHNC. TRIAL REGISTRATION: ClinicalTrials.gov ; NCT04185974 ; December 4th 2019.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Held T, Lang K, Regnery S, et al. Carbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial. Radiat Oncol. 2020. PMID: 32758267. doi:10.1186/s13014-020-01625-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。